CORE 2 --REAGENT EVALUATION, PRODUCTION AND PERMIT

Core 2的作用有三个方面：1)本SPORE项目1、2、3产生并在临床实施的药物、多肽、单克隆抗体及其衍生构建物，以及用于临床应用的活化免疫细胞的毒性、稳定性、体内定位和治疗效果的临床前评价和分析；2)临床级单抗试剂的生产；3)准备和提交具有潜在临床用途的所有试剂的研究新药（IND）许可申请。该核心提供了从实验室到临床管理的连续统一体，并确保了正在开发的试剂的有序进展和质量控制，这是我们目前在I期和II期临床试验中成功开发和实施的MAb试剂的特点。核心2的功能/具体目标如下：完整的、工程化的、偶联的和修饰的单抗构建物和免疫试剂批次的临床前评估，目前在本孢子的核心3中进行研究，包括在免疫能力和胸腺型啮齿动物肿瘤异种移植模型（包括皮下和颅内模型）中的体内稳定性、定位和治疗效果。具体目标2。针对项目1、项目2和项目3中确定的任何有希望的试剂，对衍生肽、药物和其他部分在动物模型中的体内稳定性、定位和治疗效果进行临床前分析。

The role of Core 2 is threefold: 1) the preclinical evaluation and analysis of drugs, peptides, MAbs and derived constructs, and activated immune cells for clinical application in terms of toxicity, stability, in vivo localization and therapeutic effect, generated in Projects 1, 2, and 3 of this SPORE and implemented clinically in Core 3; 2) the production of clinical grade MAb reagents; and 3) the preparation and submission of Investigational New Drug (IND) permit applications for all reagents of potential clinical utility. This Core provides a continuum from bench to clinical administration and assures the orderly progression and quality control of reagents in development that have characterized the development and implementation of our currently successful MAb reagents in Phase I and II clinical trials. The Functions/Specific Aims of Core 2 are as follows: Specific Aim 1. Pro-clinical evaluation of intact, engineered, conjugated, and modified constructs of MAbs and immunoreagent batches currently under investigation in Core 3 of this SPORE in terms of in vivo stability, localization, and therapeutic effect in immunocompetent and athymic rodent tumor xenograft models, including subcutaneous and intracranial models. Specific Aim 2. Pro-clinical analysis of derived peptides, drugs, and other moieties in terms of in vivo stabality, localization, and therapeutic effect in animal models as described in Aim 1 for any reagents of promise identified in Projects 1, 2, and 3. Specific Aim 3. Pro-clinical evaluation and quality certification of all reagents (drug, peptide, MAb, and derived constructs) generated in Projects 1, 2, and 3 and under investigation in Core 3 of this SPORE. a. Quality control by performance of, or contract for, all assays for bacterial, fungal, viral, pyrogen, and DNA contamination, and general safety tests in vivo (Core 3 immunoreagents), b. Toxicity testing and analysis of drug, peptide, MAb-toxin conjugates, nuclide-MAb conjugates and their derivatives, and effector cells in animal models (normal and athymlc rodents; Projects 1, 2 and 3; Core 3). c Determination of the maximum tolerated doses (MTD) for all substances showing no toxicity and maximal stability and therapeutic effect in athymic and normal rat and mouse model systems (subcutaneous, intracranial, CNS tumor xenografts: Projects 1 and 2). Specific Aim 4. Production of clinical grade reagents: Production of clinical grade MAb, antibody fragments, constructs, and conjugates in sufficient quantity for clinical trials conducted m Core 3. Small molecule inhibitors from Project 1 will be contracted out to GMP producers or the NCI RAID Program. Specific Aim 5. Preparation and submission of IND permit applications for all proposed therapies developed in Projects 1, 2, and 3. As the pre-clinical development Core, Core 2 has fundamental support functions for Projects 1, 2, and 3, and Cores 1 and 3.